References
- Melmed G , TarganSR, YasothanU, HanicqD, KirkpatrickP. Certolizumab pegol. Nat. Rev. Drug Discov. 7, 641–642 (2008).
- European Medicines Agency . Annex 1: Summary of product characteristics (Cimzia) (2017). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf.
- European Medicines Agency . CIMZIA European public assessment report (2015). www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001037/human_med_001294.jsp&mid=WC0b01ac058001d124.
- Mease P , FleischmannR, DeodharAAet al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase III double-blind randomised placebo-controlled study (RAPID-PsA). Ann. Rheum. Dis. 73, 48–55 (2014).
- van der Heijde D , FleischmannR, WollenhauptJet al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week Phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann. Rheum. Dis. 73, 233–237 (2014).
- Reich K , OrtonneJP, GottliebABet al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a Phase II randomized, placebo-controlled trial with a re-treatment extension. Br. J. Dermatol. 167, 180–190 (2012).
- Schreiber S . Certolizumab pegol for the treatment of Crohn’s disease. Ther. Adv. Gastroenterol. 4, 375–389 (2011).
- Landewé R , BraunJ, DeodharAAet al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24 week results of a double-blind randomized placebo-controlled Phase III study. Ann. Rheum. Dis. 73, 39–47 (2014).
- Broms G , GranathF, LinderMet al. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm. Bowel Dis. 20, 1091–1098 (2014).
- de Man YA , HazesJM, van der HeideHet al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum. 60, 3196–3206 (2009).
- Mahadevan U , SandbornWJ, LiDKet al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology133, 1106–1112 (2007).
- Norgaard M , LarssonH, PedersenLet al. Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study. J. Intern. Med. 268, 329–337 (2010).
- Jakobsson GL , StephanssonO, AsklingJet al. Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. Ann. Rheum. Dis. 75, 1838–1842 (2016).
- Gisbert JP , ChaparroM. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am. J. Gastroenterol. 108, 1426–1438 (2013).
- Hyrich KL , VerstappenSM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford)53, 1377–1385 (2014).
- Hazes JM , CouliePG, GeenenVet al. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford)50, 1955–1968 (2011).
- Maidji E , McDonaghS, GenbacevO, TabataT, PereiraL. Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am. J. Pathol. 168 (4), 1210–1226 (2006).
- Simister N . Placental transport of Immunoglobulin G. Vaccine21 (24), 3365–3369 (2003).
- Mahadevan U , WolfDC, DubinskyMet al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 11 (3), e286–e224 (2013).
- Förger F , ZbindenA, VilligerPM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients. Joint Bone Spine83 (3), 341–343 (2016).
- Porter C , Armstrong-FisherS, KopotshaTet al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J. Reprod. Immunol. 116, 7–12 (2016).
- Meso Scale Discovery . Singleplex and Multiplex Assay List (2017). www.mesoscale.com/∼/media/files/handouts/assaylist.pdf.
- Wade J , ParkerG, KosuticGet al. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn’s disease. J. Clin. Pharmacol. 55 (8), 866–874 (2015).
- DeSilva B , SmithW, WeinerRet al. Recommendations for the bioanalytical method validation of ligand binding assays to support pharmacokinetic assessments for macromolecules. Pharm. Res. 20 (11), 1885–1990 (2003).
- Shah VP , MidhaKK, FindlayJWet al. Bioanalytical method validation: a revisit with a decade of progress. Pharm. Res. 17 (17), 1551–1557 (2000).
- Viswanathan CT , BansalS, BoothBet al. Quantitative bioanalytical method and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24 (10), 1962–1973 (2007).
- Guideline on Bioanalytical Method Validation (EMEA/CHMP/EWP/192217/2009 Rev.1 Corr.2) . European Medicines Agency, London, UK (2011). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
- Guidance for industry: Bioanalytical Method Validation . Center for Drug Evaluation and Research, US FDA, MD, USA (2013). www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm368107.pdf.